Time filter

Source Type

Abingdon, United Kingdom

Tinsley J.,Summit Corporation | Robinson N.,S.H.B. Enterprises LimitedBeaconsfieldUK
Journal of Clinical Pharmacology | Year: 2015

SMT C1100 is a small molecule utrophin modulator in development to treat Duchenne muscular dystrophy. This study evaluated the safety, tolerability, and pharmacokinetics of SMT C1100 in healthy volunteers. This double-blind, placebo-controlled Phase 1 study comprised: Part 1, an escalating, single-dose with/without fasting involving 50mg/kg, 100mg/kg, 200mg/kg, and 400mg/kg doses; and Part 2, a multiple 10 day dose evaluation involving 100mg/kg bid and 200mg/kg bid doses. Adverse events were recorded. SMT C1100 was absorbed rapidly following single and multiple oral doses, with median tmax attained within 2-3.5hour across all doses. Considerable variability of pharmacokinetic parameters was noted among subjects. Following single doses, systemic exposure increased in a sub-proportional manner, with the 8.0-fold dose increment resulting in 2.7- and 2.4-fold increases in AUC0-∞ and Cmax, respectively. AUC0-∞ and Cmax were estimated as 4.2- and 4.8-fold greater, respectively, following food. Systemic exposure reduced upon repeat dosing with steady-state concentrations achieved within 3-5 days of multiple bid dosing. No serious or severe adverse events were reported. SMT C1100 was safe and well tolerated with plasma concentrations achieved sufficient to cause a 50% increase in concentrations of utrophin in cells in vitro. © 2015 The Authors. Source

This invention relates to pharmaceutical compositions comprising 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole (C1100), to processes for preparing the compositions, and to various therapeutic uses of the combinations. Also provided is a method of treatment of Duchenne muscular dystrophy or Becker muscular dystrophy using the compositions.

Summit Corporation | Date: 2013-02-07

A specialized box with integrated dividers is suitable for transporting multiple rectangular products, such as set top boxes. The box is formed of a single sheet of material, scored in six panels so that a leading panel forms a partition around which the other panels are folded and secured, with the final panel partially overlapping the second panel to form a joined side of the box. An insert with two walls, formed of a single sheet of material, can be folded into a rectangular shape and inserted in the box to create walls between the partition and each parallel side of the box. Cushioning pads can be attached to bottom flaps of the box. When flat, multiple boxes can be compactly stored or transported on a pallet. When folded into a cube, the box holds up to four rectangular products in four separate, protected compartments within the box.

Summit Corporation | Date: 2014-02-24

A lift assembly is provided. In one embodiment, the lift assembly may be used to raise and lower a bed, such as in a recreational vehicle. The lift may include a platform assembly which is movable between upper and lower positions. The lower position may be located in a lower horizontal plane than the upper position. The lift assembly may further include at least one movable member connected to the platform assembly and which may be activated to perform functions selected from the group consisting of raising the platform assembly, lowering the platform assembly, and combinations thereof. The lift assembly may also include means for positioning the platform assembly in the lower horizontal plane. In some embodiments, the means may be a cradle, while in other embodiments, the means may be a latch. The assembly may include a plurality of movable members which are activated by an electric motor.

Disclosed are compounds of formula (I): and pharmaceutically acceptable N-oxides, salts, hydrates, solvates, complexes, bioisosteres, metabolites, and prodrugs thereof, which are of use in the treatment of infection with, and diseases caused by,

Discover hidden collaborations